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Background: The prevalence of type 2 diabetes (T2D) among adults worldwide is rapidly increasing, and in
patients with diabetes the major cause of death is macrovascular disease. Endothelial cells play an important role in
maintaining vascular homeostasis. Free fatty acids, which are elevated in T2D, have previously been shown to
induce endothelial dysfunction and apoptosis of endothelial cells, which is considered as an important and early
factor in the onset of atherosclerosis and cardiovascular disease. Metformin, which is used as first line treatment of
T2D patients, is believed to exert its pharmacological effects through activation of AMP-activated protein kinase,
which has emerged as a new potential target in reversing endothelial dysfunction.
Methods: Here we studied the protective effect of metformin against free fatty acid-induced apoptosis of human
coronary artery endothelial cells (HCAECs) by assessing DNA fragmentation and cleaved caspase 3 levels. We also
attempted to elucidate the underlying mechanisms by investigating the involvement of AMP-activated protein
kinase, p38 MAPK and eNOS. Generation of reactive oxygen species by free fatty acid exposure was also examined.
Results: Our results suggest that metformin protects HCAECs from lipoapoptosis, an effect that involves eNOS and p38
MAPK, downstream of AMPK signaling, but not as previously suggested through suppression of reactive oxygen species.
Conclusion: The protective effect of metformin against free fatty acid induced apoptosis is potentially clinically relevant
as metformin is first line treatment for patients with T2D, a patient group which is rapidly increasing and carries a high
burden of cardiovascular disease.
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It is estimated that 382 million adults worldwide are
suffering from diabetes today, a number which is projected
to rise with more than 50% over the next 25 years [1]. In
patients with diabetes, the major cause of death is macro-
vascular disease, and in individuals with type 2-diabetes
(T2D), the main etiology for up to 75% of the mortality
is atherosclerotic cardiovascular disease [2]. Controlling
hyperglycemia per se has met with limited success in curb-
ing macrovascular morbidity in T2D [3], highlighting the
need to find agents effective in this respect.* Correspondence: linnea.eriksson@ki.se
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article, unless otherwise stated.The endothelium, the innermost lining of blood vessels,
is situated as a barrier between the circulating blood and
the tissue. Endothelial nitric oxide synthase (eNOS) con-
trols the vascular tone in response to several stimuli by
producing nitric oxide (NO). NO plays an essential role in
the regulation of endothelial function [4]. Loss of physio-
logical features of the endothelium, such as its preference
to support vasodilatation, fibrinolysis and antiaggregation,
is referred to as endothelial dysfunction [5]. It is oftentimes
associated with loss of NO availability and precedes the
development of atherosclerosis. This is observed in diabetic
and obese individuals, and the extent of endothelium-
dependent vasodilatation correlates with an individual’s
insulin sensitivity [4]. Endothelial dysfunction has thus
emerged as an important early target for preventing ath-
erosclerosis and cardiovascular disease [6].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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triglycerides, are known to impair the endothelial-
dependent vasodilatation [7]; and elevated levels of
FFAs are commonly seen in patients with T2D. FFAs
decrease the bioavailability of NO and induce apoptosis
of endothelial cells, two processes that are assumed to
be involved in, and contribute to, endothelial dysfunc-
tion and atherosclerosis [7,8].
In the UK Prospective Diabetes Study (UKPDS), mono-
therapy with metformin decreased the incidence of ma-
crovascular morbidity in overweight T2D patients. This
outcome appeared to be independent of its glucose lower-
ing property [9]. Metformin is believed to exert its phar-
macological effects through activation of AMP-activated
protein kinase (AMPK) [5]. AMPK has emerged as a new
potential target not only in controlling glycemia, but also in
reversing endothelial dysfunction. Activation of AMPK by
metformin has been demonstrated to lead to phosphoryl-
ation of eNOS, thus stimulating the release of NO, which is
paramount for vascular function [5,10]. In addition to this,
activation of AMPK by 5-aminoimidazole-4-carboxamide-
1-β-D-ribofuranoside (AICAR) has been shown to protect
from palmitate-induced apoptosis through suppression of
reactive oxygen species (ROS) production in bovine aortic
endothelial cells [11]. Our aim was therefore to investigate
the putative protective effect of metformin against diabetic
lipoapoptosis in human coronary artery endothelial cells
(HCAECs) and attempt to elucidate the mechanisms in-
volved in imparting such an effect.
Methods
Cell culture
Normal primary HCAECs, isolated from normal human
coronary arteries (passage 5–13) and obtained from
Clonetics (Lonza, Walkersville, MD), were grown in
EGM-2 MV medium supplemented with 5 mM glucose,
hydrocortisone, human epidermal growth factor, 5% FBS,
vascular endothelial growth factor, human fibroblast
growth factor-B, R3-IGF-1, ascorbic acid and gentamicin/
amphotericin-B at 37°C in a humidified atmosphere (5%
CO2, 95% air) as recommended by the supplier. Cell
culture experiments were approved by the local research
ethics committee (232/03). Confluent cultures were de-
tached by trypsin-2-[2-(bis(carboxymethyl) amino) ethyl-
(carboxymethyl) amino]acetic acid and seeded onto tissue
culture dishes and allowed to attach overnight before fur-
ther investigations were performed.
To examine the effect of metformin on apoptosis,
HCAECs were incubated in EGM medium containing 5%
FBS and 2 mM L-glutamine. Metformin (100 μM-2 mM)
[10,12,13], AICAR (200 μM), Compound C (10 μM), Nω-
nitro-L-arginine methyl ester hydrochloride (L-NAME,
1 mM) (Sigma-Aldrich, St Louis, MO), p38 MAPK inhibi-
tor SB203580 (10 μM) (Cell Signaling Technology, Danvers,MA), JNK inhibitor SP600125 (5 μM) (Calbiochem, La
Jolla, CA) or vehicle were added 1 h prior to palmitate
(125 μM) and were continuously present during the whole
incubation.DNA fragmentation
HCAECs were seeded onto 6 well plates and incubated for
24 h in EGM medium containing 5% FBS and 2 mM L-
glutamine, in the presence or absence of palmitate or ve-
hicle, with or without metformin, AICAR, Compound C,
L-NAME, SB203580, or SP600125. DNA fragmentation, a
marker of apoptosis, was assayed by the cell death detec-
tion kit ELISA plus (Roche Diagnostics Scandinavia AB,
Stockholm, Sweden), according to the manufacturer’s in-
structions. The ELISA measures cytoplasmic DNA-histone
complexes that increase during apoptosis-associated DNA
fragmentation.siRNA silencing of AMPK and quantitative PCR
HCAECs were seeded into 6 well plates and incubated for
24 h at 37°C in complete medium. Control siRNA and
AMPKα1/2 siRNA (final concentration 10 nM, Santa Cruz
Biotechnology, Heidelberg, Germany) was mixed and in-
cubated with SilenceMag according to the standard proto-
col by the supplier (Oz Biosciences, Marseille, France).
The siRNA/SilenceMag mix was then added drop-wise
onto the cells and incubated on a magnetic plate for
15 min, the magnet was the removed from the culture
plate and the cells were left in serum free condition for
3 h before supplementation with 5% FBS. Incubation for
the evaluation of palmitate induced apoptosis started 48 h
post transfection (as described above) and continued for
24 h.
48 h post transfection was protein and RNA isolated
from separate wells for verification of gene silencing with
western blotting (method described below) and quantitative
PCR (qPCR). RNA was prepared using Qiazol Lysis Re-
agent (Qiagen, Hilden, Germany) and purified by RNeasy
Mini kit (Qiagen, Hilden, Germany), including DNase di-
gestion. The concentration and quality was measured using
Nanodrop ND-1000 (Thermo Scientific, Waltham, MA).
For qPCR, total RNA was reverse-transcribed using High
Capacity RNA-to-cDNA kit (Applied Biosystems, Life
Technologies Corporation, Carlsbad, CA). PCR amplifica-
tion was done in 96-well plates in 7900 HT real-time PCR
system (Applied Biosystems), using TaqMan® Universal
PCR Master Mix (Applied Biosystems) and TaqMan® Gene
Expression Assays (PRKAA1 Hs01562315_m1, PRKAA2
Hs00178903_m1, Applied Biosystems). All samples were
measured in duplicates. Results were normalized to the
equal mass of total RNA as well as the Ct values of RPLPO
housekeeping control (probe Hs99999902_m1).
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Intracellular reactive oxygen species (ROS) levels were
measured using Image-iT LIVE Green Reactive Oxygen
Species Detection Kit (Molecular Probes, Life Technolo-
gies Europe BV) as previously described [14]. Briefly, the
assay is based on 5-(and-6)-carboxy-2′,7′-dichlorodihy-
drofluorescein diacetate (carboxy-H2DCFDA), a fluoro-
genic marker that will be cleaved upon the presence of
ROS. HCAECs were seeded into 6-well plates. Cells were
then incubated for 24 h in EGM medium containing 5%
FBS and 2 mM L-glutamine, in the presence or absence
of palmitate or vehicle, with or without metformin,
AICAR or Compound C. Cells were then washed with
Hank’s balanced salt solution (HBSS) before adding
25 μM carboxy-H2DCFDA to each well. After 30 minutes
of incubation at 37°C, excess probe was removed by
washing the cells again with HBSS. HCAECs were then
lysed in PBS containing 1% Triton X-100. Carboxy-DCF
fluorescence in cell lysates was detected at an excitation/
emission wavelength of 495/529 nm using a microplate
reader (Tecan Group Ltd., Männerdorf, Switzerland).
The fluorescence intensity was normalized against the
protein concentration of each individual well.
Western blot
HCAECs were incubated for up to 24 h in EGM
medium containing 5% FBS and 2 mM L-glutamine, in
the presence or absence of palmitate or vehicle, with or
without metformin, AICAR or Compound C, for the in-
dicated time points. Protein samples from cells were pre-
pared for Western blot analysis using a modified RIPA
buffer and Western blot was performed as previously de-
scribed [15]. Immunoblot analyses were performed using
antibodies that recognize phosphorylated AMPK (Cell
Signaling Technology, Danvers, MA), total AMPKα1/2
(Abcam, Cambridge, UK), phosphorylated extracellular-
signal-regulated kinase 1/2 (ERK1/2) (Millipore Corporatin,
Billierica, MA), total ERK 1/2 (Santa Cruz Biotechnology,
Heidelberg, Germany), phosphorylated p38 MAPK, total
p38 MAPK, phosphorylated c-Jun N-terminal kinase
(JNK), total JNK, phosphorylated eNOS and total eNOS,
cleaved caspase-3 (Cell Signaling Technology, Danvers,
MA). Immunoreactive bands were detected using ECL
(GE Healthcare, Uppsala, Sweden), imaged with a GelDoc
system and quantified with Quantity One software (Bio-
Rad Laboratories, Hercules, CA). To verify equal protein
loading after imaging, the polyvinylidene difluoride mem-
branes were stained with Coomassie Blue (Bio-Rad
Laboratories).
Statistical analysis
All data are expressed as mean ± SEM. For multiple com-
parisons, one-way ANOVA or non-parametric Kruskal-
Wallis one-way ANOVA on ranks, used as appropriate,the post-hoc tests Student–Newman–Keuls and Dunn’s,
were used to determine statistical probabilities of differ-
ences between groups. A value of p < 0.05 was considered
statistically significant.
Results
Activation of AMPK protects cells from lipoapoptosis
Metformin dose-dependently increased survival of cells ex-
posed to palmitate (Figure 1A). Based on these findings, we
used 500 μM of metformin for all subsequent experiments.
To further investigate if the protective effect of metformin
was AMPK-dependent, we used the specific activator of
AMPK, AICAR, and the AMPK inhibitor, Compound C.
When cells were co-incubated with AICAR and palmitate,
AICAR was able to reproduce the protective effect seen
with metformin and actually even further protect the cells
against death (Figure 1B). Conversely, co-incubation of cells
exposed to palmitate and metformin with Compound C
completely abolished the protective effect of metformin
(Figure 1C). This was further confirmed with Western blot.
Palmitate significantly increased cleaved caspase 3 levels
over time, an effect that was significant already after 16 h of
treatment (Figure 1D). The increase in cleaved caspase 3
was decreased with metformin treatment, an effect that
was mimicked by AICAR but not further reduced when
AICAR and metformin were combined. In agreement with
these findings, incubation with Compound C completely
blocked the effect of metformin on cleaved caspase 3 levels
(Figure 1E). The concentrations used herein of Compound
C and AICAR were verified to inhibit and activate AMPK,
respectively (data not shown). To further support the im-
portance of AMPK, cells were transfected with siRNA
against AMPKα1/2. As shown in Figure 1F, the protective
effect of metformin was almost completely gone with
siRNA treatment against AMPK. However not completely,
which might be due to that the AMPK protein levels were
down regulated with approximately 40% after 48 h (data
not shown).
Activation of AMPK by metformin and palmitate
To further investigate the involvement of AMPK, we stud-
ied activation by phosphorylation of AMPK in HCAECs.
Cells were incubated with or without metformin and palmi-
tate for the time points indicated in Figure 2. Metformin
activated AMPK in a time-dependent manner both in the
presence and absence of palmitate; however, the effect was
not statistically significant until after 24 h (Figure 2A and
B). Palmitate in itself was also able to activate AMPK, albeit
to a lesser extent than metformin (Figure 2B).
Treatment with metformin restores palmitate-impaired
phosphorylation of eNOS
Since FFAs impair the bioavailability of NO [7], we stud-
ied how exposure to palmitate affected activation of
Figure 1 Activation of AMPK protects human coronary artery endothelial cells from lipoapoptosis. Cells were incubated in the presence
or absence of palmitate (125 μM), metformin (A: 100 μM-2 mM), (B-E: 500 μM), with or without AICAR (200 μM) or Compound C (10 μM).
(A) Metformin protects cells from lipoapoptosis in a dose-dependent manner after 24 h, an effect that is mimicked by AICAR (B) and blocked by
Compound C after 24 h of incubation (C). Cleaved caspase 3 (CC3) levels over time (D) and in the presence or absence of metformin, AICAR
and Compound C after 24 h (E). The protective effect of metformin against palmitate-induced apoptosis is lost upon downregulation of AMPK
by siRNA transfection (F). Bars represent mean ± SEM. * p < 0.05 vs. control; # p < 0.05 vs. palmitate; § p < 0.05 vs. metformin + palmitate with
Kruskal-Wallis one-way analysis of variance on ranks. n =4-5.
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ation at Ser1177 (Figure 2C); however, after 24 h of incuba-
tion, phosphorylation levels of eNOS were significantly
decreased (Figure 2D). Conversely, co-incubation with
metformin was able to restore the reduced activation back
to control levels (Figure 2D), an effect that was mimicked
and even further enhanced by AICAR and completely
abolished in the presence of Compound C after 24 h
(Figure 2E).
Involvement of the MAPK pathways
In order to elucidate the molecular pathways contributing
to metformin’s protective effect, we studied the involve-
ment of the MAPK pathways [8]. HCAECs were incubated
with or without metformin and palmitate for the time
points specified in Figure 3 We studied how exposure to
palmitate affected extracellular-signal regulated kinases
(ERK) 1/2, JNK and p38 MAPK over time. Short exposure
to palmitate increased phosphorylation levels of p38 MAPK
(Figure 3A); however, the effect was not significant untilafter 4 h of incubation (Figure 3B). Metformin was able to
significantly reduce the increase in p38 MAPK activity after
24 h (Figure 3C), an effect that was mimicked by AICAR
and blocked by Compound C (Figure 3C). Activation of
ERK 1/2 was initially significantly increased by both palmi-
tate and metformin exposure. However, after 16 h both
palmitate- and metformin-treated cells displayed a signifi-
cantly reduced ERK 1/2 activation. There was, however, no
significant difference between cells treated with palmitate
alone and the combination of and palmitate and metformin
for 16 h (data not shown). Phosphorylated JNK levels were
significantly increased after 24 h of palmitate exposure;
treatment with metformin decreased this activation, albeit
the effect did not attain statistical significance (Figure 3D
and E).
The protective effect of metformin involves eNOS and
MAPK pathways.
Lastly we set out to further examine the involvement of
eNOS in the protective effect of metformin against
Figure 2 AMPK is activated by metformin and palmitate over time and AMPK activation restores palmitate-induced eNOS dysfunction.
Cells were incubated in the presence or absence of metformin (500 μM), with or without palmitate (125 μM), for the indicated time points. (A) Time
course showing phosphorylation levels of AMPK after 60 min, 30 min and 15 min. (B) Time course showing phosphorylation levels of AMPK after 24 h,
16 h and 4 h. (C) Phosphorylation levels of eNOS after 60 min, 30 min and 15 min. (D) Phosphorylation levels of eNOS after 24 h, 16 h and 4 h.
(E) Phosphorylation levels of eNOS in the presence or absence of metformin (500 μM), AICAR (200 μM) and Compound C (10 μM) after 24 h. Bars
represent mean ± SEM. * p < 0.05 vs. control with Kruskal-Wallis one-way analysis of variance on ranks (A, B) or one-way ANOVA (C, D, E), # p < 0.05 vs.
palmitate with one-way ANOVA. n =7 (A, C), n = 5 (B) n = 6 (D), n = 4 (E).
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JNK in lipoapoptosis. We inhibited the eNOS using the ar-
ginine analog Nω-nitro-L-arginine methyl ester hydrochlor-
ide (L-NAME), and addition of L-NAME did not affect the
basal levels of palmitate-induced apoptosis; however, upon
co-incubation with metformin the protective effect was
lost (Figure 4A). Addition of the p38 MAPK inhibitor,
SB203580 and JNK inhibitor, SP600125 significantly de-
creased the lipoapoptosis (Figure 4A), suggesting that p38
MAPK and JNK are important for the apoptosis induced
by palmitate and that modulation of these pathways is in-
volved in the protective effect seen with metformin.
The lipoprotective effect of metformin is not through
suppression of ROS
Treatment with AICAR has previously shown to protect
bovine aortic endothelial cells from palmitate-induced
apoptosis through suppression of ROS [11]. We there-
fore studied how ROS levels changed in the presence of
palmitate, metformin, AICAR and Compound C after24 h of treatment. As expected, palmitate significantly in-
creased ROS levels; however, neither co-treatment with
metformin nor AICAR affected the ROS levels generated
by palmitate (Figure 4B).
Discussion
FFAs are known to induce apoptosis of endothelial cells
[8,16] and apoptosis of endothelial cells correlates with
an impaired endothelial function [17,18], which is con-
sidered a prominent feature of atherosclerosis [19]. Our
current results suggest that metformin protects HCAECs
from lipoapoptosis caused by long-term exposure of the
cells to palmitate, an effect that is AMPK-dependent, in-
volves eNOS and p38 MAPK signaling, but not – as pre-
viously suggested – suppression of ROS formation.
Although metformin is an old antidiabetic agent and
used as first line treatment of T2D, it mechanism of ac-
tion and other effects are not fully understood. Metfor-
min has recently been shown to have some interesting
vasculoprotective effects through improvement of the
Figure 3 Palmitate-induced increase of phophorylated p38 MAPK is reduced by metformin treatment. Cells were incubated in the
presence or absence of metformin (500 μM), with or without palmitate (125 μM), for the indicated time points. (A) Phosphorylation levels of p38
MAPK after 60 min, 30 min and 15 min. (B) Phosphorylation levels of p38 MAPK after 24 h, 16 h and 4 h. (C) Phosphorylation levels of p38 MAPK
in the presence or absence of metformin (500 μM), AICAR (200 μM) and Compound C (10 μM) after 24 h. (D and E) Phosphorylation levels of
JNK p46 kDa and p55 kDa after 24 h, 16 h and 4 h. Bars represent mean ± SEM. * p < 0.05 vs. control, # p < 0.05 vs. palmitate with Kruskal-Wallis
one-way analysis of variance on ranks. n =7 (A), n = 5 (B, D, E), n = 4 (C).
Figure 4 eNOS and p38 MAPK, but not ROS levels, are involved in the protective effect of metformin. Cells were incubated for 24 h in
the presence or absence of palmitate (125 μM), with or without metformin (500 μM), L-NAME (1 mM), SB203580 (10 μM), SP600125 (5 μM), AICAR
(200 μM), Compound C (10 μM) or vehicle. (A) Metformin protects cells from lipoapoptosis, an effect that is lost upon co-incubation with L-NAME
but is mimicked by SB203580 and SP600125. (B) 25 μM of carboxy-H2DCFDA was added to each well for 30 min and ROS levels were subsequently
measured. Bars represent mean ± SEM. * p < 0.05 vs. control, # p < 0.05 vs. palmitate with Kruskal-Wallis one-way analysis of variance on ranks. n = 4
(A), n = 3 (B).
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inhibit formation of intimal hyperplasia after balloon in-
jury in fructose fed insulin resistant rats [20,21]. Also,
we have previously shown that metformin can protect
from palmitate-induced apoptosis of HCAECs [22], and
we now show that the lipoprotective effect of metformin
is conveyed through an AMPK-dependent mechanism.
The concentration of metformin in this study is high
but it was based on previous publications [10,12,13], in
order for us to compare our results to others’ findings.
In line with our data, activation of AMPK by AICAR
has previously been demonstrated to protect bovine
aortic endothelial cells from lipoapoptosis [11] and hu-
man umbilical vein endothelial cells from high glucose-
induced apoptosis [13]. As expected, metformin caused
a robust phosphorylation of AMPK, which was sus-
tained in the presence of palmitate. We also detected a
slight increase in AMPK phosphorylation upon incuba-
tion with palmitate, a phenomenon previously reported
in myocytes [23]. A possible explanation for this finding
is that palmitate is known to cause oxidative stress [11]
and oxidative stress, i.e. peroxynitrite, has in turn been
shown to activate AMPK without strict AMP depend-
ency [24,25]. Also, activation of AMPK leads to an in-
creased lipid oxidation in cells [26], and palmitate in
combination with AMPK activation enhances this oxi-
dation even further [27]. We also noticed, however the
effect was not statistically significant, that treatment
with only metformin in general gave a better response
of the cells to metformin. This might be due to the con-
dition of the cells, since palmitate treatment induces
apoptosis probably making the cells respond less effi-
ciently. Also, we have not investigated how palmitate af-
fects the phosphorylation of AMPK at Ser-485/497,
which was recently discovered to reduce phosphoryl-
ation of AMPK at Thr-172 and thus serves as a negative
regulator of AMPK activity [28].
Elevated plasma levels of FFAs are often seen in T2D
patients [8], and FFAs have been shown to impair eNOS
activity [29] and to induce endothelial dysfunction in
humans [30]. Metformin, through AMPK activation, is
able to phosphorylate eNOS and thus increase NO pro-
duction [10] and we have previously described the im-
portance of eNOS in protection against lipotoxicity of
HCAECs [16]. We therefore set out to study the effects
of palmitate on eNOS activity. Long-term exposure of
endothelial cells to palmitate decreased eNOS phosphor-
ylation [29], an effect that was countered by metformin.
This effect was completely abolished when metformin
was co-incubated with Compound C, while AICAR – on
the other hand – mimicked metformin. Adding support
to the importance of eNOS, co-incubation of metformin
and the eNOS inhibitor L-NAME almost completely
blocked the protective effect of metformin. Taken together,this suggests that metformin protects HCAECs from
lipoapoptosis through an AMPK-dependent activation of
eNOS.
JNK and p38 MAPK are stress-inducible kinases that
are known to be involved in apoptosis signaling in a var-
iety of cells [16,31,32] and p38 MAPK in particular has
been shown to be important for palmitate-induced apop-
tosis in HCAECs [8]. Metformin was able to decrease
the induced phosphorylation of p38 MAPK, an effect
that was AMPK-dependent; the effect of metformin was
also mimicked by the p38 MAPK inhibitor SB203580.
Activation of JNK was increased by FFA exposure, and
even though metformin was able to decrease this phos-
phorylation after 24 h, the effect was not statistically sig-
nificant. Incubation with a JNK inhibitor decreased the
lipoapoptosis, thus confirming the importance of JNK
activation for palmitate-induced apoptosis of HCAECs.
Taken together, our data suggest that the partial protect-
ive effect imposed by metformin is mediated through
modulation of p38 MAPK activation, downstream of
AMPK signaling.
JNK and p38 MAPK are – among other stressors – ac-
tivated by ROS [33] and since we did detect an increase
in ROS, we hypothesized that metformin might reduce
ROS as part of its lipoprotective effect. Surprisingly, we
could not detect a difference in ROS levels, neither with
metformin nor AICAR treatment. Contrary to what we
found in our study, Kim and colleagues suggested that
the lipoprotective effect of AICAR is mediated by sup-
pression of ROS [11] and others have also shown that
metformin can reduce high glucose-induced ROS [34].
The reason for this discrepancy is hard to pin down. But
in speculation, palmitate increases lipid oxidation and
can also lead to ceramide formation, two processes that
generate ROS [35]. Additionally, simultaneous activation
of AMPK increases fatty acid oxidation even further
[27]. The unchanged levels of ROS seen with metformin
might therefore reflect an increased lipid oxidation,
which contributes to its protective effect. Very recently,
it was shown that treatment with metformin, in a model
of the organism Caenorhabditis elegans, increased ROS
and β-oxidation. This effect was coupled to an increased
longevity of the worm, in which metformin-induced pro-
duction of reactive species increases the overall life ex-
pectancy [36]. Also, small fluctuations of ROS have
interestingly been suggested to play an obligatory role in
intracellular signaling [37].
Conclusion
To the best of our knowledge, this is the first report show-
ing that metformin can protect HCAECs from lipoapopto-
sis, through an AMPK-dependent mechanism, which
recover eNOS activity and decrease p38 MAPK signaling.
Our data suggest that metformin might directly improve
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tions irrespective of its glycemic effects. This finding is po-
tentially clinically relevant, since metformin is used as first
line treatment for patients with T2D, a patient group that
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